Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH.

BACKGROUNDS & AIMS Hepcidin is an acute-phase response peptide. We have investigated the possible involvement of hepcidin in massive obesity, a state of chronic low-grade inflammation. Three groups of severely obese patients with or without diabetes or nonalcoholic steatohepatitis were investigated. METHODS Hepcidin expression was studied in liver and adipose tissue of these patients. Hepcidin regulation was investigated in vitro by adipose tissue explant stimulation studies. RESULTS Hepcidin was expressed not only in the liver but also at the messenger RNA (mRNA) and the protein levels in adipose tissue. Moreover, mRNA expression was increased in adipose tissue of obese patients. The presence of diabetes or NASH did not modify the hepcidin expression levels in liver and adipose tissue. In adipose tissue, mRNA expression correlated with indexes of inflammation, interleukin-6, and C-reactive protein. Interleukin-6 also promoted in vitro hepcidin expression. A low transferrin saturation ratio was observed in 68% of the obese patients; moreover, 24% of these patients presented with anemia. The observed changes in iron status could be due to the role of hepcidin as a negative regulator of intestinal iron absorption and macrophage iron efflux. Interestingly, a feedback control mechanism on hepcidin expression related to low transferrin saturation occurred in the liver but not in the adipose tissue. CONCLUSIONS Hepcidin is a proinflammatory adipokine and may play an important role in hypoferremia of inflammation in obese condition.

[1]  N. Luciani,et al.  The Inflammatory C-Reactive Protein is Increased in Both Liver and Adipose Tissue in Severely Obese Patients Independently from Metabolic Syndrome, Type 2 Diabetes, and NASH , 2006, The American Journal of Gastroenterology.

[2]  T. Ganz,et al.  Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. , 2005, Blood.

[3]  D. Haile,et al.  Regulation of hepcidin and ferroportin expression by lipopolysaccharide in splenic macrophages. , 2005, Blood cells, molecules & diseases.

[4]  M. Rudemo,et al.  Evaluation of reference genes for studies of gene expression in human adipose tissue. , 2005, Obesity research.

[5]  E. Beutler,et al.  Regulation of hepcidin transcription by interleukin-1 and interleukin-6. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Oukka,et al.  Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Jerry Kaplan,et al.  Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization , 2004, Science.

[8]  Robert T Means,et al.  Hepcidin and anaemia. , 2004, Blood reviews.

[9]  K. Clément,et al.  The FASEB Journal • Research Communication Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects , 2022 .

[10]  S. Srai,et al.  Inhibition of iron transport across human intestinal epithelial cells by hepcidin. , 2004, Blood.

[11]  I. S. Wood,et al.  Adipokines: inflammation and the pleiotropic role of white adipose tissue , 2004, British Journal of Nutrition.

[12]  C. Vulpe,et al.  Increased hepcidin expression and hypoferraemia associated with an acute phase response are not affected by inactivation of HFE , 2004, British journal of haematology.

[13]  J. Halterman,et al.  Overweight children and adolescents: a risk group for iron deficiency. , 2004, Pediatrics.

[14]  E. Beutler,et al.  The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  N. Solanky,et al.  Effect of hepcidin on intestinal iron absorption in mice. , 2004, Blood.

[16]  M. Hentze,et al.  An Hfe-dependent pathway mediates hyposideremia in response to lipopolysaccharide-induced inflammation in mice , 2004, Nature Genetics.

[17]  Elizabeta Nemeth,et al.  IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. , 2004, The Journal of clinical investigation.

[18]  K. Yeh,et al.  Hepcidin regulation of ferroportin 1 expression in the liver and intestine of the rat. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[19]  G. Marchesini,et al.  Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver , 2004, Hepatology.

[20]  A. Aljada,et al.  Inflammation: the link between insulin resistance, obesity and diabetes. , 2004, Trends in immunology.

[21]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[22]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[23]  O. Hamdy,et al.  Adipokines, inflammation, and the endothelium in diabetes , 2003, Current diabetes reports.

[24]  Gregory J Anderson,et al.  The orchestration of body iron intake: how and where do enterocytes receive their cues? , 2003, Blood cells, molecules & diseases.

[25]  Elizabeta Nemeth,et al.  Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. , 2003, Blood.

[26]  P Lilos,et al.  Greater prevalence of iron deficiency in overweight and obese children and adolescents , 2003, International Journal of Obesity.

[27]  K. Kallen.  The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. , 2002, Biochimica et biophysica acta.

[28]  Gaël Nicolas,et al.  The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. , 2002, The Journal of clinical investigation.

[29]  R. Grimble.  Inflammatory status and insulin resistance , 2002, Current opinion in clinical nutrition and metabolic care.

[30]  W. Sly,et al.  Hepcidin: A putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Bruno Turlin,et al.  A New Mouse Liver-specific Gene, Encoding a Protein Homologous to Human Antimicrobial Peptide Hepcidin, Is Overexpressed during Iron Overload* , 2001, The Journal of Biological Chemistry.

[32]  Christina H. Park,et al.  Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the Liver* , 2001, The Journal of Biological Chemistry.

[33]  P. Morange,et al.  Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. , 2000, Diabetes.

[34]  E. Brunt,et al.  Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond , 2000, Hepatology.

[35]  S. Coppack,et al.  C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[36]  B. Rossi,et al.  Microtubule Integrity Regulates Src-like and Extracellular Signal-regulated Kinase Activities in Human Pro-monocytic Cells , 1998, The Journal of Biological Chemistry.

[37]  J S Yudkin,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-�, in Vivo* , 2022 .

[38]  B. Sobel,et al.  Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. , 1996, Circulation.

[39]  Pieter,et al.  Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. , 1995, Blood.

[40]  F. Holsboer,et al.  Soluble interleukin‐6 (IL‐6) receptor augments central effects of IL‐6 in vivo , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  P. Scheuer,et al.  Liver Biopsy Interpretation , 1973 .

[42]  C. Seltzer,et al.  SERUM IRON AND IRON-BINDING CAPACITY IN ADOLESCENTS. I. STANDARD VALUES. , 1963, The American journal of clinical nutrition.

[43]  J. Mayer,et al.  Hypoferraemia in obese adolescents. , 1962, Lancet.